Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Braeburn receives complete response letter for Brixadi in the U.S.

Dec. 3, 2020

Nirsum Laboratories presents prodrugs of opioid receptor antagonists

Dec. 1, 2020

BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice

Oct. 16, 2020

Selective PDEB inhibitor shows promising preclinical results for the treatment of cocaine addiction

Oct. 9, 2020

Sobrera and Recipharm collaborate on formulation development of SO-001 for alcohol use disorder

Sep. 29, 2020

Microglial pruning under the influence links alcohol to anxiety

Sep. 28, 2020

Proniras receives NIDA grant to pursue development of tezampanel for opioid withdrawal

Sep. 18, 2020

Embera begins phase II study of EMB-001 for cocaine use disorder

Sep. 1, 2020

FDA clears IND for phase II study of TNX-102 SL

Aug. 7, 2020

Indivior begins first-in-human study of INDV-2000 for opioid dependence

July 9, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...